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The Special Project on Pharmaceuticals in the Newly
Independent States (NIS), which includes all former
USSR countries except the Baltic countries, was
established within the WHO European Office
(Copenhagen, Denmark) in 1993 to meet the specific
needs of countries in transition from the soviet to the
market-oriented economy.
Initiatives taken since 1994
The first phase of the Special
Project consisted of fact finding
missions to make a proper assessment
• Access to essential drugs
(increase affordability, decrease
patient payments)
• Substantial improvements of
drug management in hospitals,
• New methods of financing and
reimbursement (especially for
the poor)
• Evidence based drug selection
and use
• Revision of medical and
pharmacy education and
training.
Table 1
The Patient In Focus-Priority Areas
of the situation. Based on these
reports, key problem areas were
highlighted and opportunities for
successful change and assistance
identified.
The second phase provided
assistance to Caucasian and Central
Asian Republics and at a later stage, to
the Russian Federation in a number of
key areas, namely:
• national drug policies
• legislation and regulation
• establishment of drug agencies
• quality control
• management of a market oriented
supply system
• essential drugs concept
• rational drug use
• education.
Priorities per country differed,
depending on the capacities of
available counterparts.
The third phase –The Patient in
Focus
In the third phase, starting in 1998,
the work in countries changed in line
with the conclusions of the strategy
paper The Patient in Focus.
Deteriorating health status, diminishing
budgets and increased poverty levels
asked for a larger emphasis on creating
sustainable development in a number of
areas as illustrated in Table 1.
The WHO Special Project for NIS
offers a coherent and well targeted
pharmaceuticals programme that is
problem oriented, interactive and
multidisciplinary, in addressing these
huge challenges.
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Major achievements
Within the first five years of its
inception, The Special Project for
Pharmaceuticals in NIS can boast of
number of major achievements:
• The setting up of drug laws and
regulatory agencies working in 11
NIS
• National drug policies adopted in 9
NIS
• Essential drugs available in the
private sector,
• Improved public-private
collaboration,
• Better qualified and skilled sector
management capacity
• Improved information on essential
drugs
• Tools for appropriate drug treatment
• Changes in drug financing methods
initiated in 9 NIS.
A special NIS inter-country project
component enabled all NIS to
participate and benefit from WHO
assistance and learn from experiences
in the other countries. Networking, co-
operation and problem solving capacity
clearly improved.
The future
Over the past five years the Special
Project has worked in line with the
Patient in Focus strategy. This has
resulted in successful capacity building
in different priority areas in separate
NIS as well on a Regional and NIS level.
From the first transitional period in
which NIS have developed their own
pharmaceutical sector systems and
infrastructure, the reform process is
now moving to an intensified
collaboration and networking in several
areas. Countries have now gained their
own experiences and are becoming
more interested and involved in
regional collaboration, sharing
experiences and information about
each-others achievements.
The Special Project approach can
now be described as an equal
partnership between WHO and NIS
countries, where the capacity which has
been built in each country is shared
within the NIS.
Project on the Reform and
development of pharmaceutical
Education in Central Asian
Republics: Kazakhstan, Kyrgyzstan,
Tajikistan, Turkmenistan,
Uzbekistan
It is recognized that fundamental
changes in the education system are
necessary as a result of the shift in the
pharmaceutical market from supply-
oriented to needs-driven. This demands
redefinition of healthcare professionals,
their tasks and function in the future
healthcare and drug supply system.
Since 1996, within the Special
Project on Pharmaceuticals in NIS,
there exists a Project on the Reform
and Development of Pharmaceutical
Education in Central Asian Republics
(CAR). Changing of education has
started within this project with the
training and education of decision-
makers and academics and the
redefinition of curricula. Changes have
been made in training curricula of
physicians and pharmacists first of all
in areas of drug selection and drug
prescribing. Educators have been
trained in problem-based
pharmacotherapy teaching and have
extended their experience to all
educational institutions of the CAR
region.
Close relationships among CAR
countries and constant migration of
population demands mutual recognition
of diplomas at least within CAR Region.
In spite of governmental agreements,
the mutual recognition could not have
been achieved without harmonization
of curricula. This year, during the 7th
meeting of the Network on the Reform
and Development of Pharmaceutical
Education, all participants have agreed
to adopt a credit system in line with
European standards. It will allow
countries to achieve mutual recognition
as well as to integrate international
educational systems. One of the major
resolutions of this meeting is the
setting up of an institute for the
advancement and harmonisation of
pharmaceutical education in CAR
countries. The Special Project is
currently seeking funding for the
setting up of this institute. The
milestones achieved by the Project on
the Reform and Development of
Pharmaceutical Education in Central
Asian Republics, qualify as yet another
major accomplishment for the Special
Project on Pharmaceuticals in NIS.
Funding and collaboration
The project has been able to
achieve the above mentioned goals
through funding by major donations
from the United Kingdom-Know How
Fund (UK KHF) now DFID, by the United
States International Development
Agency (USAID), and the European
Union (ECHO). Other contributors are
the German Government and the
Government of Norway. The Special
Project works in close collaboration
with the World Bank, UNICEF and TACIS
projects.
The Special Project on
Pharmaceuticals in NIS looks forward to
meeting the challenges ahead and to
achieving further significant goals. In
order to keep up this intensive work,
the Special Project is continuously
seeking financial support from
organisations willing to make
donations. This is the main means by
which the Special Project on
Pharmaceuticals in NIS can continue to
support pharmacy in these countries
and in so doing, enrich the
international pharmacy community.
